Fate Therapeutics (NASDAQ:FATE - Get Free Report)'s stock had its "hold" rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued to clients and investors on Thursday,Benzinga reports.
FATE has been the subject of several other research reports. Wall Street Zen raised shares of Fate Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 15th. Barclays cut their price target on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Wedbush reissued a "neutral" rating and issued a $5.00 price target on shares of Fate Therapeutics in a report on Thursday, March 6th. Wells Fargo & Company cut their price target on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating for the company in a report on Thursday, March 6th. Finally, Stifel Nicolaus cut their price target on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating for the company in a report on Thursday, March 6th. Eight equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $4.14.
View Our Latest Analysis on FATE
Fate Therapeutics Stock Performance
Shares of FATE traded down $0.13 during trading hours on Thursday, hitting $1.28. The stock had a trading volume of 2,427,036 shares, compared to its average volume of 2,253,089. The firm has a 50-day moving average price of $1.20 and a 200 day moving average price of $1.34. Fate Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $5.92. The firm has a market capitalization of $146.12 million, a price-to-earnings ratio of -0.77 and a beta of 2.23.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm had revenue of $1.63 million during the quarter, compared to analysts' expectations of $1.18 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. As a group, analysts predict that Fate Therapeutics will post -1.63 EPS for the current fiscal year.
Institutional Investors Weigh In On Fate Therapeutics
Large investors have recently modified their holdings of the business. Graham Capital Management L.P. purchased a new stake in shares of Fate Therapeutics during the fourth quarter worth $37,000. Brevan Howard Capital Management LP purchased a new stake in shares of Fate Therapeutics in the fourth quarter valued at about $41,000. FPC Investment Advisory Inc. purchased a new stake in shares of Fate Therapeutics in the fourth quarter valued at about $44,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Fate Therapeutics in the fourth quarter valued at about $55,000. Finally, ProShare Advisors LLC grew its holdings in shares of Fate Therapeutics by 77.9% in the fourth quarter. ProShare Advisors LLC now owns 33,645 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 14,728 shares during the period. Hedge funds and other institutional investors own 97.54% of the company's stock.
About Fate Therapeutics
(
Get Free Report)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Read More

Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.